| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
24 NKT Cells from Cancer Patients Against -Galactosylceramide1
* Department of Surgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba Science City, Ibaraki, Japan; and
Precursory Research for Embryonic Science and Technology, Kawaguchi, Saitama, Japan
Human invariant V
24+ NKT cells are a relatively new
subpopulation of lymphocytes. It has been reported that V24 NKT
cells are significantly involved in some human diseases. We have
evaluated the number and function of V24 NKT cells in both healthy
volunteers and cancer patients. In this study we found that V24 NKT
cells in unfractionated PBMCs obtained from cancer patients did not
respond efficiently to -galactosylceramide (-GalCer) in vitro.
Thus, their proportion after stimulation with -GalCer was smaller
than that found in healthy volunteers. However, the cancer patients’
V24 NKT cells retained cytotoxic activity against malignant target
cells, and they could efficiently proliferate to -GalCer when
fractionated by sorting. Furthermore, we found that addition of G-CSF
to the culture could restore the low proliferative response of V24
NKT cells from cancer patients. These results suggest that some
functions of NKT cells in cancer patients are impaired, and this
observation carries significant implications for immunotherapy-based
cancer treatments.
This article has been cited by other articles:
|
|
 |
|
  K. Yanagisawa, M. A. Exley, X. Jiang, N. Ohkochi, M. Taniguchi, and K.-i. Seino Hyporesponsiveness to Natural Killer T-Cell Ligand {alpha}-Galactosylceramide in Cancer-Bearing State Mediated by CD11b+ Gr-1+ Cells Producing Nitric Oxide Cancer Res., December 1, 2006; 66(23): 11441 - 11446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Motohashi, A. Ishikawa, E. Ishikawa, M. Otsuji, T. Iizasa, H. Hanaoka, N. Shimizu, S. Horiguchi, Y. Okamoto, S.-i. Fujii, et al. A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer Clin. Cancer Res., October 15, 2006; 12(20): 6079 - 6086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms. Clin. Cancer Res., August 15, 2006; 12(16): 4794 - 4803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Atkins, D. E. Elder, R. Essner, K. T. Flaherty, T. F. Gajewski, F. G. Haluska, P. Hwu, U. Keilholz, J. M. Kirkwood, J. W. Mier, et al. Innovations and challenges in melanoma: summary statement from the first cambridge conference. Clin. Cancer Res., April 1, 2006; 12(7): 2291s - 2296s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Crough, M. Nieda, and A. J. Nicol Granulocyte Colony-Stimulating Factor Modulates {alpha}-Galactosylceramide-Responsive Human V{alpha}24+V{beta}11+ NKT Cells J. Immunol., October 15, 2004; 173(8): 4960 - 4966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Sandberg, C. A. Stoddart, F. Brilot, K. A. Jordan, and D. F. Nixon Development of innate CD4+ {alpha}-chain variable gene segment 24 (V{alpha}24) natural killer T cells in the early human fetal thymus is regulated by IL-7 PNAS, May 4, 2004; 101(18): 7058 - 7063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Metelitsa, H.-W. Wu, H. Wang, Y. Yang, Z. Warsi, S. Asgharzadeh, S. Groshen, S. B. Wilson, and R. C. Seeger Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2 J. Exp. Med., May 3, 2004; 199(9): 1213 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Dhodapkar, M. D. Geller, D. H. Chang, K. Shimizu, S.-I. Fujii, K. M. Dhodapkar, and J. Krasovsky A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma J. Exp. Med., June 16, 2003; 197(12): 1667 - 1676. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
